title: Neo-adjuvant hormone therapy for non-metastatic prostate cancer: a systematic review and meta-analysis of 5,194 patients.
abstract: BACKGROUND
  Neo-adjuvant hormone therapy (NHT) following radical prostatectomy (RP) or radiotherapy has been utilized in the multimodal approach to patients with intermediate- to high-risk prostate cancer (PCa). Herein, we performed a systematic review and meta-analysis of published randomized trials to evaluate the clinical efficacy of NHT.
  
  
  METHODS
  Literatures were searched from PubMed, EMBASE, Web of Science, and Cochrane Library for comparing neo-adjuvant therapy group (NHT plus radiotherapy or radical prostatectomy) with traditional therapy (radiotherapy or prostatectomy) alone. Quality of the research was assessed on the basis of the Cochrane's risk of bias of randomized controlled trial. Comparable information were obtained from eligible trials and assembled for meta-analysis up to 31 August 2014. RevMan 5.2 software was used for statistical analysis.
  
  
  RESULTS
  Fifteen randomized controlled trials (RCTs) (total 5,194 patients) were included in this study. Meta-analysis showed there was a significant improvement in overall survival (OS) (Odds ratio (OR) = 1.51, 95% confidence interval (CI) 1.22 to 1.87, P = 0.0002), positive surgical margin (PSM) rate (OR = 0.30, 95% CI 0.24 to 0.38, P < 0.00001), and biochemical disease-free survival (bDFS) (OR = 1.95, 95% CI 1.13 to 3.39, P = 0.02), but no significant difference in disease-free survival (OR = 1.52, 95% CI 0.90 to 2.59, P = 0.12) and clinical disease-free survival (cDFS) (OR = 0.96, 95% CI 0.22 to 4.18, P = 0.95). Heterogeneity and risk of bias were observed between different studies.
  
  
  CONCLUSIONS
  Patients with aggressive prostate cancer would better benefit from the receipt of neo-adjuvant therapy. Physicians should make individualized treatment strategies according to adverse reactions, financial capacities, and personal wishes.
authors.affiliation: Department of Urology, Huashan Hospital, Fudan University, No.12 WuLuMuQi Middle Road, 200040, Shanghai, People's Republic of China. jimeng1214@126.com.
authors.forename: Jimeng
authors.initials: J
authors.lastname: Hu
authors.affiliation: Department of Urology, Huashan Hospital, Fudan University, No.12 WuLuMuQi Middle Road, 200040, Shanghai, People's Republic of China. norman.xu@hotmail.com.
authors.forename: Hua
authors.initials: H
authors.lastname: Xu
authors.affiliation: Department of Urology, Huashan Hospital, Fudan University, No.12 WuLuMuQi Middle Road, 200040, Shanghai, People's Republic of China. 12211220025@fudan.edu.cn.
authors.forename: Wenhui
authors.initials: W
authors.lastname: Zhu
authors.affiliation: Department of Urology, Huashan Hospital, Fudan University, No.12 WuLuMuQi Middle Road, 200040, Shanghai, People's Republic of China. uro_wf@163.com.
authors.forename: Fei
authors.initials: F
authors.lastname: Wu
authors.affiliation: Department of Urology, Huashan Hospital, Fudan University, No.12 WuLuMuQi Middle Road, 200040, Shanghai, People's Republic of China. wjq-077@163.com.
authors.forename: Jianqing
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Urology, Huashan Hospital, Fudan University, No.12 WuLuMuQi Middle Road, 200040, Shanghai, People's Republic of China. dingqiang_uro@126.com.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Ding
authors.affiliation: Department of Urology, Huashan Hospital, Fudan University, No.12 WuLuMuQi Middle Road, 200040, Shanghai, People's Republic of China. haowenj73@126.com.
authors.forename: Haowen
authors.initials: H
authors.lastname: Jiang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic